ArticlePloS one2026
Designing a multi-epitope vaccine against La Crosse virus using immunoinformatics approach.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
La Crosse virus (LACV) is a mosquito-borne Orthobunyavirus responsible for pediatric encephalitis, with no currently approved vaccine or targeted antiviral therapy. This study aimed to design a multi-epitope subunit vaccine targeting the conserved nucleoprotein of LACV using an integrated immunoinformatics approach. The nucleoprotein exhibited strong antigenicity and favorable physicochemical properties, including stability and hydrophilicity. Highly conserved CTL, HTL, and B-cell epitopes were initially predicted, from which high-affinity, non-allergenic, and non-toxic epitopes were selected. Population coverage analysis revealed extensive global applicability, with MHC class I and II coverage of 98.55% and 81.81%, respectively. Three vaccine constructs (V1, V2 and V3) were developed, while construct V1 demonstrated superior performance, with the highest antigenicity (0.7846) and solubility (0.709). Structural validation confirmed stability, with over 93% of residues in favored regions of the Ramachandran plot. Molecular docking with the TLR8 receptor revealed strong interactions. This was further supported by MD simulations, DCCM analysis, binding free energy calculations, and PCA, all of which confirmed stable binding between the vaccine construct V1 and TLR8, exhibiting a docking score of -1212.6. Molecular dynamics simulations further confirmed stability, with consistent RMSD, stable radius of gyration, and persistent hydrogen bonding (40-60 bonds). Codon optimization demonstrated favorable translational efficiency and confirmed the suitability of the construct V1 for heterologous expression in E. coli. Immune simulation predicted robust humoral and cellular responses, including elevated IgM, IgG, and cytokines. Overall, the proposed vaccine candidate V1 demonstrates strong immunogenic potential and structural stability, warranting further experimental validation for potential clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.